Vitae Pharmaceuticals, Inc. IPO Advisory
Share this IPO Profile:
Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
Vitae Pharmaceuticals, Inc. | VTAE - NASDAQ |
$11.00-$13.00 |
$8.00 |
$8.00 | 6.875 million | 9/24/2014 |
Stifel, BMO Capital Markets |
Co-Manager(s): JMP Securities, Wedbush PacGrow Life Sciences |
Health Care |
Filing(s): Filed 2014-08-12 Terms Added 2014-09-08
|
For IPO Boutique's "scale of 1 to 5" BUY rating on Vitae Pharmaceuticals, Inc., and our comprehensive analysis, click "Buy Market Research".
Vitae Pharmaceuticals, Inc. Quote & Chart - Click for current quote -
VTAE
About Vitae Pharmaceuticals, Inc. (adapted from Vitae Pharmaceuticals, Inc. prospectus):
They are a clinical stage biotechnology company focused on discovering and developing novel, small molecule drugs for diseases that represent large market opportunities where there are significant unmet medical needs.
This description is adapted from Vitae VTAE prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as Vitae VTAE "VTAE" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
© 2005 - 2024 IPO Boutique. All Rights Reserved